Skip to main content
SLAS2024 Main banner
Sartorius Ad
Back

Eberhard Krauß, Dr

ChemBioCon, Hessen, Germany

Dr. Eberhard Krausz, ChemBioCon (Germany)
Since 2018, Eberhard Krausz is working for Evotec (France) as a group leader in target validation and early drug discovery (oncology). In 2014, Eberhard co-founded and implemented VIB Discovery Sciences enabling to translate basic research outcomes into early drug discovery programmes. Previously, he has been supporting scientists and teams during various positions in industry (Tibotec, J&J/Janssen) and academia in technology selection, target identification & validation, development particularly of physiologically more relevant cell-based assays, screening, and drug discovery. In 2003-2008, he was setting-up and heading the central high-content screening labs at the Max Planck Institute in Dresden, Germany. Before, he held responsible positions in biotech industry at Cenix BioScience (Germany) and Cyclacel (Scotland, UK) dealing with RNA interference and drug discovery, respectively.
In his private time, Eberhard loves teaching courses under his brand name ChemBioCon. Eberhard is a SLAS Fellow member since 2022. He has been serving several committees and councils at SLAS and formerly SBS, e.g. the Membership and Engagement Council most recently.

Disclosure information not submitted.

Presentation(s):